Vivani Medical (NASDAQ:VANI) Posts Earnings Results, Hits Expectations

Vivani Medical (NASDAQ:VANI) posted its quarterly earnings results on Wednesday. The company reported ($0.08) EPS for the quarter, meeting analysts’ consensus estimates of ($0.08), FiscalAI reports.

Vivani Medical Trading Up 1.8%

VANI stock traded up $0.02 on Wednesday, hitting $1.16. The company had a trading volume of 108,889 shares, compared to its average volume of 334,017. Vivani Medical has a 12-month low of $0.92 and a 12-month high of $1.92. The stock’s 50-day simple moving average is $1.18 and its 200 day simple moving average is $1.31.

Insider Transactions at Vivani Medical

In related news, Director Gregg Williams bought 1,587,301 shares of the company’s stock in a transaction that occurred on Wednesday, April 15th. The shares were bought at an average price of $1.26 per share, for a total transaction of $1,999,999.26. Following the completion of the acquisition, the director owned 32,944,484 shares of the company’s stock, valued at $41,510,049.84. This trade represents a 5.06% increase in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Corporate insiders own 53.30% of the company’s stock.

Institutional Investors Weigh In On Vivani Medical

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Tudor Investment Corp ET AL bought a new position in Vivani Medical in the fourth quarter worth approximately $1,127,000. Marshall Wace LLP bought a new position in Vivani Medical in the fourth quarter worth approximately $174,000. Geode Capital Management LLC raised its position in Vivani Medical by 29.6% in the fourth quarter. Geode Capital Management LLC now owns 461,652 shares of the company’s stock worth $568,000 after acquiring an additional 105,398 shares during the period. Renaissance Technologies LLC raised its position in Vivani Medical by 118.4% in the fourth quarter. Renaissance Technologies LLC now owns 97,985 shares of the company’s stock worth $121,000 after acquiring an additional 53,127 shares during the period. Finally, Jane Street Group LLC bought a new position in Vivani Medical in the fourth quarter worth approximately $60,000. Hedge funds and other institutional investors own 6.78% of the company’s stock.

Analysts Set New Price Targets

Separately, HC Wainwright cut their price target on shares of Vivani Medical from $4.00 to $3.50 and set a “buy” rating on the stock in a report on Tuesday, March 31st. One equities research analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Vivani Medical presently has an average rating of “Hold” and an average target price of $3.50.

About Vivani Medical

Vivani Medical Solutions, Inc (NASDAQ: VANI) is a medical technology company focused on the design, development and commercialization of advanced specimen retrieval and hemostasis products for minimally invasive diagnostic procedures. Its core mission is to enhance procedural safety and streamline clinical workflows for interventional radiologists and pathology laboratories.

The company’s flagship offerings include the StopBleed Retrieval Device and StopBleed Pad, which integrate proprietary hemostatic materials to control bleeding at biopsy sites and preserve tissue integrity.